Radiopharm Theranostics' RAD 101 Hits 90% Concordance in Brain Metastases Trial — Radiopharm Theranostics Limited

Event summary

RAD 101 achieved 90% concordance between PET imaging and MRI in 20 patients in Phase 2b trial for brain metastases.
First five patients show positive trends in sensitivity and specificity at six-month follow-up.
Final data readout from 30-patient study expected by June 2026.
RAD 101 has FDA Fast Track Designation for distinguishing recurrent disease in brain metastases.

The big picture

Radiopharm Theranostics' RAD 101 addresses a critical diagnostic gap in neuro-oncology, where CE-MRI limitations leave ~300,000 U.S. patients annually without optimal imaging solutions. The 90% concordance rate positions RAD 101 as a potential standard in distinguishing recurrent disease from treatment effects, with implications for precision oncology workflows.

What we're watching

Regulatory Pathway: Whether the positive interim data will accelerate FDA approval timelines for RAD 101.
Clinical Validation: The pace at which full 30-patient data readout confirms sensitivity and specificity trends.
Market Positioning: How RAD 101's differentiation in brain metastases imaging impacts competitive dynamics.